October 2020
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

Early detection is key in the fight against cancer. Since most therapy is focused around treating cells at the site of origin, it is important to detect cancerous cells as early as possible, before it has had the chance to metastasize.

Therefore, having testing procedures to detect cancer at the initial onset is vital to successfully eliminate the disease.

The most effective screening test would possess attributes such as being non-invasive, safe, reliable, and inexpensive.

The Pap smear is one of the first screening tests available for cervical cancer and has since become routine for women during yearly pelvic exams.

This procedure is inexpensive and relatively non-invasive although it may be uncomfortable for some.

However, the reliability is scrutinized due to the incident of false positives where cells are wrongly diagnosed as cancerous.

This screening procedure requires subjective analysis by a cytologist reading hundreds of samples a day, at this point, human error becomes inevitable.

Despite the shortcomings, most would agree that they would elect to take the test.

Other diagnostic procedures include imaging techniques, endoscopy, and biopsy.

Imaging techniques, such as x-ray and MRI, are not invasive like endoscopy and biopsies, but most of these techniques are only effective at later stages in cancer development for obvious reasons.

Many of these procedures are used as a final definitive screen in diagnosis because they do carry some patient risk.

The field of biomarker screening in biological fluids such as blood and urine has really become the focal point of cancer research for early detection.

The routinely used prostate-specific antigen (PSA) and Cancer Antigen CA-125 screens measure individual biomarkers.

Although these are good screening tools, the new wave of biomarker screening is focused on forms of testing that can cover a broad spectrum of cancer types in one analysis.

Tumors shed exosomes into the blood supply and these exosomes carry genetic material and proteins that can reveal the type and progression of cancer.

Therefore, the origin of the cancer can be detected. Both of these revolutionary tests can detect cancer very early, even before clinical symptoms are presented.

The future of screening and diagnostic testing looks promising and provides another valuable tool to fight cancer.

These early detection capabilities are especially promising for those types that can only be detected at later stages when clinical symptoms arise and survival rates are low.

These procedures are high-throughput and all-encompassing so new cancer types will be added as additional markers are found.

As research continues in the area of high-throughput biomarker screening, early detection will certainly save millions of lives.

Comments are closed.

Special Procedures

Click on Any Topic

Bone Marrow Transplants

Organ Transplants

Stem Cells

——————————————–

Euthanasia

Physician Assisted Suicide

Medical Topics
  • Long-Term Data Back Anti-PD-1 in Advanced Non-Squamous NSCLC
    (MedPage Today) -- Long-term data from an early first-line trial of pembrolizumab (Keytruda) plus chemotherapy showed that more than half of patients with advanced non-squamous non-small cell lung cancer (NSCLC) remained alive at 3 years. In cohort...
  • Suze Orman's Schwannoma
    (MedPage Today) -- Financial advisor, author and former CNBC host Suze Orman has always stressed that it is a mistake for people to ignore their money problems. Now she wants you to know that "the most vital and stupid mistake I could ever make...
  • 'License' to Smoke After Negative Lung Screening?
    (MedPage Today) -- Some individuals appear to interpret a negative low-dose CT (LDCT) lung screening scan as a green light to resume smoking, a post hoc analysis of the National Lung Screening Trial (NLST) found. For example, highly nicotine dependent...
  • Hunting Resistance Mechanisms in RET-Fusion Lung Cancer
    (MedPage Today) -- As detected by circulating tumor DNA (ctDNA), acquired resistance to pralsetinib (Gavreto) in RET fusion-positive lung cancer was relatively uncommon, findings from the ARROW study suggested. In 42 non-small cell lung cancer...
  • Dual Checkpoint Blockade With Some Chemo Boosts OS in NSCLC
    (MedPage Today) -- A first-line immune checkpoint inhibitor combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) improved survival in patients with advanced non-small cell lung cancer (NSCLC) when added to a limited course of chemotherapy...
Content Protected Using Blog Protector By: PcDrome.